Clinical Scorecard: Identification of a Unique cyp51A Mutation in Aspergillus fumigatus from a Patient with Systemic Lupus Erythematosus and Limited Systemic Sclerosis: The First Report of Acquired Azole Resistance in Colombia

At a Glance

Key Highlights

• First clinical case of acquired azole-resistant Aspergillus fumigatus reported in Colombia.
• Unique cyp51A gene mutation identified, expanding known resistance polymorphisms beyond TR34/L98H and TR46/Y12F/T289A.
• Azole resistance developed after prolonged voriconazole therapy in an immunocompromised patient, leading to fatal invasive aspergillosis.

Guideline-Based Recommendations

Diagnosis

• Consider Aspergillus infection in immunocompromised patients with respiratory symptoms and persistent fever.
• Use serum Aspergillus galactomannan antigen testing and bronchoalveolar lavage culture for diagnosis.
• Perform antifungal susceptibility testing to detect azole resistance, especially after treatment failure.

Management

• Initiate voriconazole as first-line therapy for chronic pulmonary aspergillosis.
• Switch to alternative antifungal agents such as intravenous caspofungin upon identification of azole resistance.
• Empiric broad-spectrum antibiotics may be used initially but should be reassessed based on microbiological findings.

Monitoring & Follow-up

• Monitor serum Aspergillus galactomannan antigen levels to assess treatment response.
• Perform serial imaging (CT scans) to evaluate pulmonary lesions and disease progression.
• Regular clinical assessment for respiratory symptoms and signs of infection exacerbation.

Risks

• Long-term voriconazole use can select for azole-resistant Aspergillus fumigatus strains.
• Immunosuppression increases susceptibility to invasive aspergillosis and worsens prognosis.
• Delayed recognition of resistance may lead to treatment failure and increased mortality.

Patient & Prescribing Data

Immunocompromised adults with systemic lupus erythematosus and limited systemic sclerosis receiving corticosteroids and immunosuppressants.

Prolonged voriconazole therapy may lead to emergence of azole-resistant Aspergillus fumigatus, necessitating antifungal susceptibility testing and alternative treatments.

Clinical Best Practices

• Perform antifungal susceptibility testing routinely in cases of aspergillosis with poor clinical response.
• Consider early use of alternative antifungal agents when resistance is suspected or confirmed.
• Maintain vigilance for fungal infections in immunocompromised patients and monitor closely for treatment efficacy.

References

• Aspergillus fumigatus and azole resistance epidemiology
• Clinical management of invasive aspergillosis